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Renewed global efforts towardmalaria eradication have highlighted the need for novel antimalarial agents with activity against
multiple stages of the parasite life cycle. We have previously reported the discovery of a novel class of antimalarial compounds in
the imidazolopiperazine series that have activity in the prevention and treatment of blood stage infection in a mouse model of
malaria. Consistent with the previously reported activity profile of this series, the clinical candidate KAF156 shows blood schi-
zonticidal activity with 50% inhibitory concentrations of 6 to 17.4 nM against P. falciparum drug-sensitive and drug-resistant
strains, as well as potent therapeutic activity in a mouse models of malaria with 50, 90, and 99% effective doses of 0.6, 0.9, and 1.4
mg/kg, respectively. When administered prophylactically in a sporozoite challenge mouse model, KAF156 is completely protec-
tive as a single oral dose of 10 mg/kg. Finally, KAF156 displays potent Plasmodium transmission blocking activities both in vitro
and in vivo. Collectively, our data suggest that KAF156, currently under evaluation in clinical trials, has the potential to treat,
prevent, and block the transmission of malaria.
Widespread resistance to most antimalarial drug classes hasled to a global adoption of artemisinin-based combination
therapies (ACTs) as first-line therapies (1, 2). However, recent
reports of delayed rates of parasite clearance after administration
of artemisinin derivatives raise concerns that ACTs efficacy might
soon be compromised (3–7). In addition to having to overcome
artemisinin resistance, next-generation antimalarial drugs are also
expected to target multiple stages of the parasite life cycle. The
Malaria Eradication Agenda Initiative has defined the ideal anti-
malarial drug profile as a Single Encounter Radical Cure and Pro-
phylaxis (SERCaP) therapy that could be used in mass adminis-
tration programs (8). Upon administration of a single dose,
SERCaP therapy should eliminate all asexual and sexual (mature
gametocyte) blood stages of the parasite, as well as the hepatic
forms, thereby providing a combined therapeutic radical cure,
disease-transmission blocking and prophylactic activities (9, 10).
There are currently very few antimalarial drugs with the pharma-
cological profile required for these next-generation therapies (11).
As an initial step toward development of a next-generation
antimalarial therapy, we have previously described the imidazol-
opiperazines, a novel class of antimalarial drugs class with potent
blood-stage (12) and liver-stage (13) activity. Here, we describe
the preclinical antimalarial profile of the drug candidate, KAF156,
which emerged from an extensive lead-optimization program of
the imidazolopiperazine class (14). Compared to other com-
pounds in its class, KAF156 was selected for its overall superior
profile which balances the adequate physicochemical properties
required for oral tablet formulation and excellent antimalarial
properties. Like other imidazolopiperazine compounds, KAF156
has potent activity on blood and hepatic stage parasites which
translates into therapeutic and prophylactic activity in mouse
models of infection. Furthermore, KAF156 displays cidal activity
against mature Plasmodium falciparum gametocytes and thus
blocks parasite transmission to Anopheles mosquitoes. Taken to-
gether, our data suggest that KAF156 combined with other anti-
malarial drugs could be used in malaria elimination campaigns to
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prevent infection, treat acute disease and reduce transmission of
the parasite.
MATERIALS AND METHODS
Maintenance of P. falciparum cultures. P. falciparum parasites were cul-
tured in O red blood cells in RPMI 1640 media (without phenol red)
containing L-glutamine and supplemented with 50 g of gentamicin/ml,
14mg of hypoxanthine/liter, 38.4mMHEPES, 0.2% sodium bicarbonate,
0.2% glucose (pH 7.2), 5% human serum, and 0.25% Albumax II. Cul-
tures weremaintained at 5%hematocrit at a parasitemia of 1 to 10%, with
daily media changes (15). Fresh blood was drawn at least every 2 weeks,
and cultures were maintained under 96% nitrogen, 3% carbon dioxide,
and 1% oxygen at 37°C.
Antimalarial proliferation inhibition assay (384-well plate format).
A20-l portion of screeningmedium (culturingmediumwithout human
serum but supplemented with 0.5% Albumax II) was dispensed via a
MicroFlo (BioTek) liquid dispenser into 384-well, black, clear-bottom
assay plates (Clear GNF custom plates; Griener Bio-One). Then, 50-nl
portions of compounds in a dose-response format were transferred by
using a PlateMate Plus (Matrix) or the PinTool (GNF Systems). Each
parasite strain was diluted to 0.3% parasitemia and 4.2% hematocrit and
dispensed (30 l) into prewarmed assay plates by using the MicroFlo
liquid dispenser. The final parasitemia and hematocrit were 0.3 and 2.5%,
respectively. Assay plates were incubated at 37°C for 72 h under 96%
nitrogen, 3% carbon dioxide, and 1% oxygen. After 72 h, a prepared
mixture of lysis buffer (5 mM EDTA, 1.6% Triton X-100, 20 mM Tris-
HCl, 0.16% saponin) inwater and 0.1%SYBRgreen detection reagentwas
dispensed at 10 l per well using the MicroFlo. Cultures were incubated
for an additional 24 h at 25°C before measuring the fluorescence intensity
using an Envision plate reader (Perkin-Elmer) with a 505 dichroicmirror.
The excitation and emission filters were 485 and 530 nm, respectively. The
data were normalized based on the maximum fluorescence signal values
for dimethyl sulfoxide (DMSO)-treated wells (no inhibition by com-
pound) and the minimum fluorescence signal values for wells containing
the highest concentration of inhibitor control compounds. The 50% in-
hibitory concentrations (IC50s) were obtained by using a curve-fitting
model with standard logistic regression.
Clinical isolate schizont maturation assay. Field isolates were col-
lected from theMae Sot region of Tak Province (Thailand) in 2009 (10 P.
vivax and 13 P. falciparum) and Timika, Southern Papua (Indonesia), in
2011 (20 P. vivax and 26 P. falciparum). All samples were from patients
with acute malaria (with a monospecies parasitemia of 2,000 to 10,000
parasites/l) attending outpatient clinics. After written consent was ob-
tained, blood samples were collected by venipuncture into heparinized
tubes and processed within 5 h of collection. Ethical approval for this
project was provided by theHuman Research Ethics Committee,Menzies
School of Health Research, Darwin, Australia (HREC 2010-1396); the
Eijkman Institute Research Ethics Commission, Jakarta, Indonesia
(EIREC-47); the University of Oxford, Centre for Clinical Vaccinology
and TropicalMedicine, United Kingdom (XTREC 027-025); and the Eth-
ics Committee of the Faculty of Tropical Medicine, Mahidol University,
Bangkok, Thailand (MUTM 2008-215). Samples with 80% early rings
were chosen for drug sensitivity testing. After the platelets and leukocytes
were removed, drug sensitivity and stage-specific activity were tested as
previously described (16, 17). Drug plate quality was assured by running
schizont maturation assays with the chloroquine-resistant strain K1 and
the chloroquine-sensitive strain FC27. Dose-response curves and IC50
values were calculated by fitting the data to a sigmoidal inhibitory Emax
pharmacodynamicmodel usingWinNonLin (v4.1; Pharsight Corp.). The
median IC50s were compared nonparametrically using the Kruskal-Wallis
test. Statistical analyses and graphics were carried out using GraphPad
Prism 5 software (version 5).
P. falciparum gametocyte maturation. NF54 cultures were initiated
in a tipper system in a suspension of 5% group 0 red cells in culture
medium with an asexual parasite density of 0.5%, and the medium was
replaced daily (18–20). Asexual parasites and gametocytes were moni-
tored regularly using Giemsa-stained blood films. At day 8, all cultures
containing 3 to 4% asexual parasite-infected red blood cells, 2.5% stage II
gametocytes, and 2.4% stage III/IV gametocyte stages (total gameto-
cytemia of 4.9%)were pooled. Purificationmethods were not used for the
removal of asexual parasites to avoid potential negative effects on game-
tocyte maturation and infectivity. Compound was added from days 8 to
12withmedium replacement twice daily and replaced by controlmedium
at 48 h before the standardmembrane feeding assay (SMFA). The number
of mature gametocytes was determined at day 13, as well as the capacity of
male gametocytes to exflagellate after temperature drop and addition of
fetal calf serum (21). Cultures with exflagellating gametocytes and/orma-
ture gametocytes were fed in the SMFA to mosquitoes on day 14.
Transmission blocking assays. The SMFAwas used to test the poten-
tial effects of compounds or drugs on parasite sporogony in the mosquito
as previously described (22, 23). Briefly, 14-day-old cultures of strain
NF54 showing 0.3 to 0.5%mature gametocytes were first checked for their
quality and potential to form oocysts in a preliminary test feed to anoph-
elesmosquitoes.When ookinetes were seen 22 h after the feeding, parasite
culture material was used to test the potential effects of compounds on
sporogony. First, 300l of culturematerial was added to 180l of washed
packed cells and then centrifuged for 20 s. Next, after removal of the
supernatant, 150 l of human control serum with or without test com-
pound was added to the pellet. Each suspension was immediately injected
into an individual membrane-covered minifeeder and 20 3- to 5-day-old
Anopheles stephensimosquitoes were allowed to feed for 10 to 15 min. Six
days after feeding, 20 mosquitoes per feeder were dissected. Absolute
numbers of oocysts were counted by light microscopy after staining the
mosquito stomach with 2% mercurochrome. Oocyst numbers were cal-
culated as the arithmetic mean of the number of oocysts of 20 dissected
mosquitoes and represent the transmission-reducing activity of the com-
pounds tested. The in vivo assessment of transmission blocking activity
was performedwith rodent parasites as follows. This study was conducted
in accordance with U.S. animal welfare regulations under a protocol ap-
proved by the University of California at San Diego Institutional Animal
Care and Use Committee. Mice were infected with 5  105 P. berghei
ANKA 676m1cl1 parasites on day 0 via an intraperitoneal injection. The
mice were then dosed with 100 mg of KAF156/kg (formulated in 0.5%
[wt/vol] methylcellulose [Sigma-Aldrich, catalog no. M0262] and 0.5%
[vol/vol] Tween 80) or vehicle control orally on day 5 when the para-
sitemia reached 5 to 6%. Feedswere completed 24 h later onday 6.Oocysts
were counted by light microscopy after the mosquito stomachs were
stained with 2% mercurochrome.
P. yoelii liver-stage antimalarial assay.This assay has previously been
described (13). In brief, P. yoelii (17XNL) sporozoites were obtained after
salivary gland dissection of infected A. stephensi mosquitoes supplied by
the New York University Insectary. Dissected salivary glands were ho-
mogenized in a glass tissue grinder, filtered twice through nylon cell
strainers (40-mpore size; BDFalcon), and counted using a hemocytom-
eter. Then, 7.5  103 HepG2-A16-CD81EGFP cells in 50 l of medium
(1.5  105 cells/ml) were seeded in 384-well plates (Aurora 384 IQ-EB
black/clear plates) 20 to 26 h prior to the actual infection. Two hours prior
to infection, 50 nl of compound in DMSO (0.1% final DMSO concentra-
tion per well) were transferred with a PinTool (GNF Systems) into the
assay plates (10 M final concentration). Atovaquone, an exo-erythro-
cytic schizonticidal approved drug (10M)and 0.1%DMSOwere used as
positive and negative controls, respectively. The HepG2-A16-CD81EGFP
cells were then infected with 8 103 sporozoites per well, and the plates
were spun down at 650 g.After infection and 1 h of incubation at 37°C,
the cultures were washed, newmedia and compound were added, and the
cultures were further incubated with 5-fold-increased concentrations of
penicillin-streptomycin for 48 h at 37°C. Infected cells were quantified by
immunofluorescence. About 8,000 sporozoites were used to infect one
well, and the infected HepG2-A16-CD81EGFP cells were exposed for 48 h
to compounds at a 10 M concentration dissolved in DMSO. About half
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of the total area of a well was imaged, which on average covered about 50
infected cells.
In vivo mouse causal prophylaxis efficacy assay. These experiments
were conducted at the USAMC-AFRIMS facility (accredited by the Asso-
ciation for Assessment and Accreditation of Laboratory Animal Care In-
ternational) in Bangkok, Thailand. In brief, mice (five per experimental
group) received test compound on day 0, 2 h before parasite inoculation.
Control animals received the same amount of vehicle without drug.
Atovaquone, an approved prophylactic antimalarial drug, was used as a
positive control. We have previously established that atovaquone, when
administered as a single oral dose of 2.5 mg/kg, is fully protective in this
model (unpublished data). On day 0, all ICR (outbred stock) mice were
infected by a standard 0.1-ml dose of 105 P. berghei sporozoites by intra-
venous inoculation. Blood smear samples were obtained on days 4, 5, 6, 7,
10, 15, 21, and 31 postinoculation. Mice were observed twice daily for
clinical signs and mortality. On day 7 and afterward, animals with para-
sitemia exceeding 5% were euthanized. In a dose-ranging study, KAF156
was dosed orally in a suspension formulation of 0.5%, (wt/vol) methyl-
cellulose, and 1% (wt/vol) Solutol HS15 at 1, 5, 10, or 15 mg/kg. The
prophylactic activity was monitored through blood smear analysis and is
expressed in terms of mouse survival over 30 days.
In vivo mouse therapeutic efficacy assay. All in vivo efficacy studies
were approved by the veterinary authorities of the Canton Basel-Stadt.
The in vivo antimalarial activity was usually assessed for groups of five
female NMRI mice (20 to 22 g) intravenously infected on day 0 with 2
107 erythrocytes parasitized with P. berghei green fluorescent protein
(GFP)-expressing parasites (PbGFPCON, kindly donated by A. P.Waters
and C. J. Janse, Glasgow and Leiden Universities) (24, 25) (for reference
compounds, see Table 1 and also Table S2 in the supplemental material)
or the P. berghei ANKA reference strain (for all other studies). From his-
torical data, untreated control mice died typically between days 6 and 7
postinfection, but in these studies all animals showing unabated para-
sitemia or malaria symptoms were humanely euthanized on day 4 with
CO2. Experimental compounds were formulated in 7% (vol/vol) Tween
80–3% (vol/vol) ethanol, 10% ethanol (vol/vol), 30% (wt/vol) PEG400,
60% (wt/vol) Vit E TPGS (Eastman), or 5% (wt/vol) SolutolHS15 (BASF)
as indicated. Compounds were administered orally in a volume of 10
ml/kg as a single dose (24 h postinfection), as three consecutive daily doses
(24, 48, and 72 h postinfection), or as four consecutive doses (6, 24, 48,
and 72 h postinfection). With the single-dose regimen we determined the
parasitemia at 72 h postinfection, and for the triple- and quadruple-dose
regimens we determined the parasitemia at 96 h postinfection using stan-
dard flow cytometry techniques or standardmicroscopy (25). The activity
was calculated as the difference between themean percent parasitemia for
the control and treated groups expressed as a percentage of the control
group. The survival time in days was also recorded up to 30 days after
infection. A compound was considered curative if the animal survived to
day 30 after infection with no detectable parasites.
In vitro resistance selection. A clonal population of P. falciparum
strain Dd2 was used to initiate three independent parasite cultures under
the initial selection pressure of 1.8 nM KAF156 (flask/strain 1, 2, and 3).
Parasitemia was monitored daily, and the compound concentration was
increased 2-fold when parasitemia reached3%. After 1 month of selec-
tion, each culture was split into two cultures (culture 1, 1A and 1B; culture
2, 2A and 2B; and culture 3, 3A and 3B) in an attempt to accelerate resis-
tance development in each pair by increasing the concentration2-fold
(“B” strains) generating ultimately six resistant strains after 4 months of
continuous culture in increasing concentrations of KAF156. For each of
the six resistant strains, the single-nucleotide polymorphisms (SNPs)
were detected by either whole genome sequencing (Illumina technology)
or capillary sequencing (see below).
The susceptibility of each resistant strain to KAF156, GNF707, and
GNF452 (the GNF707 and GNF452 chemical structures and synthesis are
described elsewhere [13]) was determined, and the fold shift in efficacy
(i.e., the phenotypic susceptibility shift) was calculated.
For determination of the resistance frequency, cloned lines of Dd2
(1pa) and FCR3 were cultured in complete RPMI 1640 medium (0.5%
Albumax) in various volumes (2 to 320ml). Parasites were pressured with
3 IC50 in a single-step selection and cultured for either 60 days or until
resistant parasites emerged under selection. Prior to selection, the starting
parasite cultures were expanded to1.5 liters in multiple flasks, pooled,
and distributed according to the appropriate starting inoculum. Predom-
inantly ring-stage cultures were exposed to drug, and cultures were fed
daily for 6 days and every other day thereafter until the emergence of
parasites.
Drug-resistant mutants genomic analysis. The design of PCR prim-
ers to amplify a single gene we named P. falciparum Cyclic Amine Resis-
tance Locus (pfcarl; PlasmoDB ID PFC0970w) for Sanger sequencing was
problematic due to the high percentage of AT nucleotides in this gene.
We therefore designed long PCR primers around the gene, avoiding high
AT regions, to amplify two overlapping fragments spanning 5.9 kb
total (primer sequences below). Sequencing libraries were made from
these fragments using Nextera library preparation kits (Illumina, San Di-
ego, CA). Paired 60-bp reads were generated on an IlluminaGAIIx instru-
ment. Reads were aligned to the P. falciparum strain Dd2 using SOAP
(26).Nucleotide changes from the reference sequencewere calledwhere at
least six separate reads called the alternate letter, and the sum of the Illu-
mina quality scores of the alternate letter from all reads containing that
letter were 5 the sum of the Illumina quality score of the reference letter
in all of the reads that contained that letter. A new reference sequence was
generated with these SNP changes, and the reads were aligned with SOAP
against the improved genomic sequence; new SNPs were discovered, and
this process was iterated nine times. The long PCR primer sequences were
as follows: pfc970w_long1F, TTTGTCTTTTCTAGTTATAATGATTT;
pfc970w_long1R, GATCTGTAGTAATAACTGATTGTGGTGAAT;
pfc970w_long2F, TTTTGTCTTTTCTAGTTATAATGATTTTTTAAAA
AACTAAAAGAAGCAC; and pfc970w_long2R, GTCAAAAGATCTGTA
GTAATAACTGATTGTGGTGAAT.
RESULTS
KAF156potently inhibits blood stagesofPlasmodium species. It
was previously shown that KAF156 (Fig. 1) has low nanomolar
potency in inhibiting the growth of laboratory-adapted P. falcip-
arum strains cultured in human erythrocytes (6 to 17 nM IC50)
using a 72-h SYBR green proliferation assay (14). This activity
range is maintained over a broad panel of strains resistant to one
or more current antimalarial drugs (see Table S1 in the supple-
mental material).
We extended these studies to clinical isolates of P. vivax and P.
falciparum collected frommalaria patients on the Thai-Myanmar
border and Papua Indonesia, wheremultidrug resistance has been
reported in both P. falciparum and P. vivax (27–30). An ex vivo
schizont maturation assay (16) was used to measure activity on
asexual development. Across the two Thai and Indonesian sites
the overall median IC50 values were 12.6 nM (range, 3.5 to 27.1
nM) against P. falciparum and 5.5 nM (range, 1.4 to 65.8 nM)
against P. vivax (Fig. 2). At both sites, drug susceptibility to
FIG 1 Chemical structure of KAF156.
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KAF156 was significantly greater than that for chloroquine but
less that than for artesunate (P  0.001 in Kruskal-Wallis analy-
sis).
We have previously reported therapeutic activity for KAF156
in a malaria mouse model (14), using the P. berghei GFP express-
ingANKA-strain (25) and, for reasons that remain unclear, we did
not observe a dose-dependent increase inmouse survival with this
parasite strain. In contrast, when the original P. berghei ANKA
strain (without the GFP transgene) was used, KAF156 achieved
sterilizing activity upon administration of four daily 100-mg/kg
doses in 9 of 10 mice, with no detectable parasites 30 days after
infection (Table 1). This does not appear to be driven by an in-
trinsically higher drug sensitivity of the ANKA parasite, since oral
dosing of KAF156 reduced blood parasitemia with potency (50%
effective dose [ED50] 0.6mg/kg, ED90 0.9mg/kg, and ED99
1.4 mg/kg [reported in Table S2 in the supplemental material])
comparable to what we have previously observed with the GFP-
ANKA strain (14). Nonetheless, our data collectively show that
KAF156 is at least as effective as some of the current antimalarial
drugs for the treatment of an acute blood-stage malaria infection.
Generation and characterization of KAF156 drug-resistant
mutants in vitro. The development of drug resistance has histor-
ically rapidly limited the efficacy and therefore the use of many
approved antimalarial drugs. To assess the potential for develop-
ing resistance to imidazolopiperazines and using the stepwise
drug resistance selection method previously reported (13), we se-
lected P. falciparum clones for resistance to KAF156 and some
related compounds (Table 2). Consistent with our previous find-
ings, targeted sequencing analysis of these clones showed that all
resistant lines had acquired SNPs in a single gene we named pfcarl
(PlasmoDB ID PFC0970w), encoding an uncharacterized protein
conserved across Plasmodium species with seven predicted trans-
membrane regions (13). Unlike the earlier derivatives GNF707
and GNF452, KAF156 generally displayed potent activity against
almost all of the drug resistant clones (Table 2). The only excep-
tion was the clone bearing the pfcarl S1076I mutation, to which
KAF156 proved considerably less potent.
Notably, whereas standard drugs remain potently active (see
Table S3 in the supplemental material), earlier imidazolopipera-
zine analogs were found generally to be inactive against the
KAF156-resistant strains. In one of theseKAF156-resistant clones,
we identified two novel SNPs (see Fig. S1 in the supplemental
material), namely, S1076R and P822T, that in combination
shifted the potency of KAF156 to an IC50 of 73 nM (40-fold
higher than against the sensitive parental line). However, of all the
SNPs identified, substitution of the serine at position 1076with an
isoleucine appears to be themost detrimentalmutation, yielding a
drug sensitivity shift to KAF156 of700-fold.
In order to estimate the frequency of drug resistancemutations
in P. falciparum, we used the method of minimal inoculum for
resistance that is an indirect measurement of the probability of a
resistant genotype to occur (31).We selected for spontaneousmu-
tants emerging from cultures of both Dd2 and FCR3 strains by
exposing a range of starting inocula (1 106 to 4 109 parasites)
to constant drug pressure at 3 IC50 for 60 days. Under these
conditions, we observed drug-resistant parasites emerging only
from Dd2 cultures containing more than 108 parasites (see Table
S4 in the supplemental material). Again, targeted sequencing
analysis revealed that all KAF156-resistant clones with a signifi-
cant shift in potency carried nonsynonymous SNPs in the pfcarl
gene (I1139K or Q821H). Collectively, our data suggest that in
vitro selection of resistant mutations to KAF156 arise in the pfcarl
gene with a frequency of 1 per 108 parasites with the Dd2 P.
falciparum strain.
KAF156 has potent activity on liver-stage parasites in vitro
and has prophylactic activity in vivo.We have previously shown
that imidazolopiperazines inhibit the growth of the exo-erythro-
cytic forms in an in vitro assay using CD81-expressing HepG2
hepatoma cells infected with rodent P. yoelii liver-stage parasites
(13). Similarly, KAF156 displayed potent activity in this assay with
an IC50 of 2 nM against intrahepatic schizonts.
In the causal prophylactic rodent malaria model, mice are in-
travenously infected with P. berghei sporozoites that target the
liver. After an incubation period of 48 h, the P. berghei liver schi-
zonts will release merozoites that initiate blood-stage infection
and cause symptoms of disease within 5 or 6 days. In this model, a
single oral dose of 10 mg of KAF156/kg administered 2 h before
infection was fully protective (Fig. 3) (14).
FIG2 Drug sensitivity of P. vivax (Œ) and P. falciparum () clinical isolates to
chloroquine, artesunate, and KAF156. An ex vivo schizont maturation assay
was used to measure the drug sensitivity of clinical isolates in Thailandfor P.
vivax (n 10) and P. falciparum (n 13) isolates (A) and in Indonesia for P.
vivax (n 20) and P. falciparum (n 26) (B). The horizontal bar represents
the median IC50, and its numerical value is indicated above (nM).
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KAF156 inhibits gametocytogenesis and blocks transmis-
sion to the Anopheles mosquito. The completion of the sexual
phase of the Plasmodium life cycle in infected red blood cells yields
fully mature stage V female and male gametocytes that are trans-
mitted to the Anopheles mosquito. We evaluated the activity of
KAF156 against gametocyte formation and their transmission to
the mosquito vector. Early-stage gametocytes treated with
KAF156 on days 8 to 12 after the induction of gametocytogenesis
showed a significant dose-dependent reduction in the total num-
ber of stage V gametocytes (Fig. 4A). These data suggest that the
compound is a potent inhibitor of gametocyte maturation in vitro
at concentrations as low as 50 nM. Consistent with this observa-
tion,when fed tomosquitoes through a standardmembrane-feed-
ing assay (SMFA) (23), all three cultures treated with 5 nM
KAF156 yielded zero oocysts (Fig. 4B). Taken together, the data
suggest that KAF156 has a profound effect on the final and critical
steps of gametocytematuration exflagellation. This range of activ-
ity against Plasmodium sexual stages is at least comparable to, if
not superior to, what has been reported before with approved
antimalarial drugs (32, 33).
We also evaluated KAF156 transmission blocking potential.
Viable and fullymature stageV gametocytes were incubated for 15
min with various KAF156 concentrations and fed to mosquitoes
through an SMFA. In this assay, KAF156 showed a clear dose-
dependent effect with 90% reduction of oocyst numbers at a
concentration of 500 nM (Fig. 4C). Notably, the compound had
no adverse effects onmosquito viability.We then confirmed these
observations in vivo in a P. berghei rodent malaria model. Infected
mice treated with a single dose oral of KAF156 at 100 mg/kg were
found to be not infectious to Anopheles mosquitoes feeding on
their blood (see Fig. S2 in the supplemental material). Taken to-
gether, our results demonstrate that KAF156 inhibits the matura-
tion of P. falciparum sexual stages and effectively blocks parasite
transmission to Anopheles mosquitoes.
DISCUSSION
Cell-based screening is a well-established method for the discov-
ery of new anti-infective drugs and has been historically successful
for antimalarial drug discovery (34). Given the large number of
novel antimalarial scaffolds recently discovered that target asexual
TABLE 1 In vivo efficacy of KAF156 in a P. berghei rodent malaria
modela
Dose(s) (mg/kg) Compoundb
Mean	 SD
Cure
(%)dActivity (%)
Mouse survival
(days)c
1 30 Chloroquine* 99.9	 0.07 9.6	 0.8 0
Mefloquine* 99.6	 0.5 21.8	 2.1 0
Artesunate* 92.4	 2.9 9.0	 1.2 0
KAF156† 99.9	 0.006 16.7	 2.8 0
1 100 Chloroquine* 99.9 12.7 0
Artesunate* 99.9	 0.08 8.8	 0.8 0
KAF156† 99.9	 0.008 23.4	 4.3 10
3 30 Chloroquine‡ 99.9	 0.02 14.0	 0.0 0
Mefloquine‡ 98.6	 0.3 18.8	 1.3 0
Artesunate‡ 99.0	 0.3 11.8	 3.3 0
3 50 KAF156† 99.99 29.4	 0.8 40
4 100 KAF156† 99.99 29.8	 0.6 90
a A comparison of single- and multiple-dose efficacies with standard antimalarials or
KAF156 was performed. For single-dose efficacy, the mice were dosed 24 h after
infection. The percent parasitemia was measured 72 h after infection, and mouse
survival was monitored. For multiple-dose efficacy,the mice were dosed daily for 3 days
(24, 48, and 72 h after infection) or 4 days (6, 24, 48, and 72 h after infection [see
column 1]) at theindicated doses. The percent parasitemia was measured 96 h after
infection, and mouse survival was monitored. GFP-ANKA was used in the reference
study with chloroquine, mefloquine, and artesunate, and parasitemia was determined
by fluorescence-activated cell sorting analysis. No significant differences were observed
with GFP-ANKA and ANKA strains for these compounds. Data are means calculated
from two independent experiments, with n 5 mice for each experiment.
b *, Ethanol-Tween 80-water (3/7/90); †, 5% Solutol HS15; ‡, 10% ethanol, 30%
PEG400, 60% Vit E TPGS.
c The survival of control animals was 6 to 7 days.
d Cure, no parasites present at day 30.
TABLE 2 In vitro resistance mechanism of KAF156a
Selection
agent Culture SNP(s)b
Mean IC50 (nM)	 SD
GNF707 GNF452 KAF156
DMSO None (Dd2, WT) 8.1	 0.9 7.6	 2.0 1.8	 0.6
GNF707 1R V1254F 170 49 2.0
2R L830V 150 61 2.0
3R E834D 1,300 360 36
GNF452 1R M1069I, L830V 3,600 1,200 97
3R S1076I, L830V 2,600 7,300 3,600
KAF156 1AR Q821H, S1076R 5,300 1,900 10
1BR P822T, S1076R 10,000 10,000 73
2BR S1076I 3,000 10,000 1,600
3AR E834D 6,900 1,800 24
3BR E834D 5,000 1,600 16
a Five independent cultures of P. falciparum strain Dd2 were cultured in the presence of
increasing concentrations of KAF156 over 4 months and, in a similar manner, three
independent cultures were pressured with GNF707, and two independent cultures were
pressured with GNF452. Parasitemia was monitored daily, and the compound
concentration was increased 2-fold when the parasitemia reached3%. For each of the
resistant strains, the SNPs detected and the antimalarial activities (IC50) are as indicated
for KAF156, GNF707, and GNF452. Data are presented to two significant figures as the
median value from two to four independent experiments; the IC50s were consistent
within 1.5-fold across experiments.
b SNPs, single-nucleotide polymorphisms. SNPs were confirmed by capillary
sequencing of pfcarl (PFC0970w).
FIG 3 KAF156 is fully protective in a causal prophylactic mouse model of
malaria. Mice (n 5) were infected with P. berghei sporozoites intravenously
on day 0 and administered a single dose of compound 2 h before parasite
inoculation. Mice were monitored over 30 days for parasitemia. Vehicle used
for compound administration was a suspension formulation of 0.5% (wt/vol)
methylcellulose and 1% (wt/vol) Solutol HS15. The data represent the num-
bers of live mice at the indicated day postinfection.
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blood stages (35–38), identifying compounds in these sets that are
also active on liver stages and mature gametocytes will allow for
the discovery of next-generation antimalarials, compatible with
the SERCaP target product profile. Indeed, there are several recent
reports of phenotypic assays suitable for screening compounds for
activity against liver schizonts (13, 39), gametocytes (32, 40), and
possibly hypnozoites (41, 42).
We show here that the clinical candidate KAF156, optimized
for its potent blood-stage activity, is also fully protective in a liver-
stage mouse model of malaria and blocks disease transmission.
Screening of asexual erythrocytic actives with orthogonal assays
for sexual and liver stages has greatly facilitated next-generation
antimalarial drug discovery. Currently, very few drug targets have
been chemically validated across the parasite life cycle (43–45). It
will thus be important to apply these screens to all available asex-
ual blood-stage hits since the identification of compounds active
across multiple stages will help define the parasite genome rele-
vant for the discovery of next-generation antimalarial drugs. In-
deed, numerous postgenomic tools are now available to identify
the molecular targets of novel antimalarials (46). The overlap of
the parasite proteome between all stages is predicted to be small
(47–49). Thismay be because only themost abundant proteins are
detected by full genome proteomic methods.
The discovery of the imidazolopiperazines is thus significant,
since the determination of their mechanism of action and their
molecular target would provide opportunities to rationally screen
for and design compounds targeting sexual and hepatic stages. In
a first step toward the deconvolution of this series’ mechanism of
action, we selected for drug-resistant parasites in vitro and identi-
fied nonsynonymous SNPs in pfcarl, which encodes a protein of
unknown function with seven putative transmembrane domains
(see Fig. S1 in the supplemental material) (13). It is worth noting
that the PfCARL protein is expressed during asexual and sexual
blood stages (49, 50). Previously reported expression studies also
indicate that the PfCARL ortholog in P. berghei is expressed in
gametocytes, as well as in the blood and liver stages (47). Muta-
tions in PfCARL are specific to imidazolopiperazines and do not
result in resistance to other classes of drugs (see Table S3 in the
supplemental material). It is thus tempting to speculate that Pf-
CARL is the direct molecular target of KAF156; however, we can-
not currently rule out that PfCARL may act as a transporter for
imidazolopiperazine. This remains to be determined with further
experiments aiming to elucidate the function of the pfcarl gene
product.
Consistent with our inability to raise drug-resistant parasites
with the African FCR3 clone and the moderate frequency of
KAF156 drug-resistant mutations in the Southeast Asian Dd2
clone, none of the SNPs identified have been previously reported
in clinical isolates (PFC0970w search at http://plasmodb.org).
This suggests that the KAF156 drug-resistant mutations are rare
and that the amino acids involved are functionally important.
Nonetheless, our data show that significant resistance can be ac-
quired with a few SNPs. Since this compound is moving toward
clinical development, the identification of a suitable drug partner
will be crucial, and it will be important to monitor the possible
emergence of mutations in the pfcarl locus and particularly at
position 1076. Indeed, the set of SNPs reported here will be valu-
able to assess the drug resistance liability and help devise a drug
combination strategy to minimize this risk.
KAF156 has favorable drug-like properties with pharmacoki-
FIG 4 KAF156 inhibits gametocyte development and blocks parasite trans-
mission to mosquitoes. Three (A and B) or two (C) independent experiments
were carried out, and the mean values are reported on bar graphs with the
standard error of themean indicated. (A) Cultures of immature stage II game-
tocytes were treated with various concentrations of KAF156 on days 8 to 12
after the induction of gametocytogenesis. The negative control (KAF156 con-
centration 0 nM) cultures were treated with DMSO (vehicle) at a 0.1% final
concentration. The total number of mature stage V gametocytes (males and
females) per 5,000 erythrocytes was assessed bymicroscopy on day 13 for each
experiment. (B) An SMFA was used to evaluate the transmission potential of
parasites cultures treated on days 8 to 12. (C) Viable and fully mature stage V
gametocytes (males and females) were treated with KAF156 on day 15 after
induction and fed through SMFA to mosquitoes. For both panels B and C, no
toxicity to mosquitoes was observed at any of the compound concentrations,
and the number of oocysts in the midgut of an infectedmosquito was counted
for at least 20 infectedmosquitoes for each independent experiment. An aster-
isk (*) indicates that the mean is significantly different (P  0.05) from the
untreated control in a one-way analysis of variance, followed by a Dunnett’s
multiple-comparison test.
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netics in preclinical species compatible with once-daily dosing
and no significant in vitro safety liabilities (14). Recently, the com-
pound went through an extensive Good Laboratory Practices
safety and pharmacological preclinical assessment that supported
progression to human clinical trials. If KAF156 is shown to be safe
and effective, it could be the first new antimalarial drug combining
potent prophylactic, therapeutic, and transmission-blocking ac-
tivities—a significant addition to the armamentarium for the ma-
laria eradication agenda.
ACKNOWLEDGMENTS
We gratefully acknowledge funding and support from the Wellcome
Trust (translational research grants WT078285 and WT096157) and the
Medicines for Malaria Venture (MMV) to the Genomics Institute of the
Novartis Research Foundation, the Swiss Tropical and Public Health In-
stitute, and the Novartis Institute for Tropical Diseases. Funding was also
obtained from the Singapore Immunology Network (SIgN) and from the
Horizontal Programme on Infectious Diseases under the Agency for Sci-
ence, Technology, and Research (A*STAR, Singapore). Shoklo Malaria
Research Unit (SMRU) is sponsored by The Wellcome Trust of Great
Britain, as part of the Oxford Tropical Medicine Research Programme of
Wellcome Trust-Mahidol University. The laboratory studies in Papua
were funded by MMV and a Wellcome Trust Fellowship awarded to
R.N.P. (grant 091625).
We thank Julie Lotharius and Xavier Ding for coordinating the com-
pound testing in the David Fidock and Ric Price laboratories through
additional MMV funding.
No funding bodies had any role in study design, data collection, and
analysis, the decision to publish, or the preparation of the manuscript.
Kelli Kuhen, Kerstin Gagaring, Zhong Chen, Advait Nagle, Whitney
Barnes,David Plouffe, JohnWalker,DavidTully, Jennifer Taylor, Richard
Glynne, and Thierry Diagana are current Novartis employees. Arnab
Chatterjee, Rachel Borboa, Jennifer Buenviaje, Carolyn Francek, Eliza-
beth Winzeler, and Tao Wu have previously been employed by Novartis.
Richard Glynne, Elizabeth Winzeler, and Thierry Diagana own Novartis
shares and stock options.
REFERENCES
1. World Health Organization. 2010. Guidelines for the treatment of ma-
laria. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2013. World malaria report 2013. World
Health Organization, Geneva, Switzerland.
3. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Don-
dorp AM, Day NP, White NJ, White LJ. 2009. The last man standing is
the most resistant: eliminating artemisinin-resistant malaria in Cambo-
dia. Malar. J. 8:31. http://dx.doi.org/10.1186/1475-2875-8-31.
4. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM,
Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M,
Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P,
Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resis-
tance in Plasmodium falciparum malaria. N. Engl. J. Med. 361:455–467.
http://dx.doi.org/10.1056/NEJMoa0808859.
5. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. 2008.
Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl.
J. Med. 359:2619–2620. http://dx.doi.org/10.1056/NEJMc0805011.
6. Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, Al Saai
S, Phyo AP, Moo CL, Lwin KM, McGready R, Ashley E, Imwong M,
Stepniewska K, Yi P, Dondorp AM, Mayxay M, Newton PN, White NJ,
Nosten F, Ferdig MT, Anderson TJ. 2012. A major genome region
underlying artemisinin resistance in malaria. Science 336:79–82. http:
//dx.doi.org/10.1126/science.1215966.
7. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R,
ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day
NP, White NJ, Anderson TJ, Nosten F. 2012. Emergence of artemis-
inin-resistant malaria on the western border of Thailand: a longitudi-
nal study. Lancet 379:1960–1966. http://dx.doi.org/10.1016/S0140-6736
(12)60484-X.
8. malERA Consultative Group on Drugs. 2011. A research agenda for
malaria eradication: drugs. PLoS Med. 8:e1000402. http://dx.doi.org/10
.1371/journal.pmed.1000402.
9. Kappe SH, Vaughan AM, Boddey JA, Cowman AF. 2010. That was then
but this is now: malaria research in the time of an eradication agenda.
Science 328:862–866. http://dx.doi.org/10.1126/science.1184785.
10. White NJ. 2008. The role of anti-malarial drugs in eliminating malaria.
Malar. J. 7(Suppl 1):S8. http://dx.doi.org/10.1186/1475-2875-7-S1-S8.
11. Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA,
Sinden RE, Leroy D. 2012. The activities of current antimalarial drugs
on the life cycle stages of Plasmodium: a comparative study with human
and rodent parasites. PLoS Med. 9:e1001169. http://dx.doi.org/10.1371
/journal.pmed.1001169.
12. Wu T, Nagle A, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z,
Plouffe D, Goh A, Lakshminarayana SB, Wu J, Ang HQ, Zeng P, Kang
ML, Tan W, Tan M, Ye N, Lin X, Caldwell C, Ek J, Skolnik S, Liu F,
Wang J, Chang J, Li C, Hollenbeck T, Tuntland T, Isbell J, Fischli C,
Brun R, Rottmann M, Dartois V, Keller T, Diagana T, Winzeler E,
Glynne R, Tully DC, Chatterjee AK. 2011. Imidazolopiperazines: hit to
lead optimization of new antimalarial agents. J. Med. Chem. 54:5116–
5130. http://dx.doi.org/10.1021/jm2003359.
13. Meister S, Plouffe DM, Kuhen KL, Bonamy GM, Wu T, Barnes SW,
Bopp SE, Borboa R, Bright AT, Che J, Cohen S, Dharia NV, Gagaring
K, Gettayacamin M, Gordon P, Groessl T, Kato N, Lee MC, McNamara
CW, Fidock DA, Nagle A, Nam TG, Richmond W, Roland J, Rottmann
M, Zhou B, Froissard P, Glynne RJ, Mazier D, Sattabongkot J, Schultz
PG, Tuntland T, Walker JR, Zhou Y, Chatterjee A, Diagana TT,
Winzeler EA. 2011. Imaging of Plasmodium liver stages to drive next-
generation antimalarial drug discovery. Science 334:1372–1377. http://dx
.doi.org/10.1126/science.1211936.
14. Nagle A, Wu T, Kuhen K, Gagaring K, Borboa R, Francek C, Chen Z,
Plouffe D, Lin X, Caldwell C, Ek J, Skolnik S, Liu F, Wang J, Chang J, Li
C, Liu B, Hollenbeck T, Tuntland T, Isbell J, Chuan T, Alper PB, Fischli C,
Brun R, Lakshminarayana SB, Rottmann M, Diagana TT, Winzeler EA,
Glynne R, Tully DC, Chatterjee AK. 2012. Imidazolopiperazines: lead op-
timization of the second-generation antimalarial agents. J. Med. Chem. 55:
4244–4273. http://dx.doi.org/10.1021/jm300041e.
15. Trager W, Jensen JB. 1976. Human malaria parasites in continuous
culture. Science 193:673–675. http://dx.doi.org/10.1126/science.781840.
16. Russell BM, Udomsangpetch R, Rieckmann KH, Kotecka BM, Coleman
RE, Sattabongkot J. 2003. Simple in vitro assay for determining the sen-
sitivity of Plasmodium vivax isolates from fresh human blood to antima-
larials in areas where P. vivax is endemic. Antimicrob. Agents Chemother.
47:170–173. http://dx.doi.org/10.1128/AAC.47.1.170-173.2003.
17. Russell B, Chalfein F, Prasetyorini B, Kenangalem E, Piera K, Suwana-
rusk R, Brockman A, Prayoga P, Sugiarto P, Cheng Q, Tjitra E, Anstey
NM, Price RN. 2008. Determinants of in vitro drug susceptibility testing
of Plasmodium vivax. Antimicrob. Agents Chemother. 52:1040–1045.
http://dx.doi.org/10.1128/AAC.01334-07.
18. Ponnudurai T, Lensen AH, Leeuwenberg AD, Meuwissen JH. 1982.
Cultivation of fertile Plasmodium falciparum gametocytes in semi-
automated systems. 1. Static cultures. Trans. R. Soc. Trop. Med. Hyg.
76:812–818. http://dx.doi.org/10.1016/0035-9203(82)90116-X.
19. Ponnudurai T, Meuwissen JH, Leeuwenberg AD, Verhave JP, Lensen
AH. 1982. The production of mature gametocytes of Plasmodium falcip-
arum in continuous cultures of different isolates infective to mosquitoes.
Trans. R. Soc. Trop. Med. Hyg. 76:242–250. http://dx.doi.org/10.1016
/0035-9203(82)90289-9.
20. Ponnudurai T, Verhave JP, Meuwissen JH. 1982. Mosquito transmission
of cultured Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. 76:
278–279. http://dx.doi.org/10.1016/0035-9203(82)90298-X.
21. van Schaijk BC, Kumar TR, Vos MW, Richman A, van Gemert GJ, Li
T, Eappen AG, Williamson KC, Morahan BJ, Fishbaugher M, Kennedy
M, Camargo N, Khan SM, Janse CJ, Sim KL, Hoffman SL, Kappe SH,
Sauerwein RW, Fidock DA, Vaughan AM. 2014. Type II fatty acid
biosynthesis is essential for Plasmodium falciparum sporozoite develop-
ment in the midgut of anopheles mosquitoes. Eukaryot. Cell 13:550–559.
http://dx.doi.org/10.1128/EC.00264-13.
22. Kone A, van de Vegte-Bolmer M, Siebelink-Stoter R, van Gemert GJ,
Dara A, Niangaly H, Luty A, Doumbo OK, Sauerwein R, Djimde AA.
2010. Sulfadoxine-pyrimethamine impairs Plasmodium falciparum game-
tocyte infectivity and Anopheles mosquito survival. Int. J. Parasitol. 40:
1221–1228. http://dx.doi.org/10.1016/j.ijpara.2010.05.004.
Kuhen et al.
5066 aac.asm.org Antimicrobial Agents and Chemotherapy
23. van der Kolk M, De Vlas SJ, Saul A, van de Vegte-Bolmer M, Eling WM,
Sauerwein RW. 2005. Evaluation of the standardmembrane feeding assay
(SMFA) for the determination of malaria transmission-reducing activity
using empirical data. Parasitology 130:13–22. http://dx.doi.org/10.1017
/S0031182004006067.
24. Fidock DA, Rosenthal PJ, Croft SL, Brun R, Nwaka S. 2004. Antima-
larial drug discovery: efficacy models for compound screening. Nat. Rev.
Drug Discov. 3:509–520. http://dx.doi.org/10.1038/nrd1416.
25. Franke-Fayard B, Trueman H, Ramesar J, Mendoza J, van der Keur M,
van der Linden R, Sinden RE, Waters AP, Janse CJ. 2004. A Plasmodium
berghei reference line that constitutively expresses GFP at a high level
throughout the complete life cycle. Mol. Biochem. Parasitol. 137:23–33.
http://dx.doi.org/10.1016/j.molbiopara.2004.04.007.
26. Li R, Li Y, Kristiansen K, Wang J. 2008. SOAP: short oligonucleotide
alignment program. Bioinformatics 24:713–714. http://dx.doi.org/10.1093
/bioinformatics/btn025.
27. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin
M, Zaw T, Annerberg A, de Radigues X, Nosten F. 2008. Plasmodium
vivax resistance to chloroquine in Dawei, southern Myanmar. Trop.
Med. Int. Health 13:91–98. http://dx.doi.org/10.1111/j.1365-3156.2007
.01978.x.
28. White NJ. 1992. Antimalarial drug resistance: the pace quickens. J. Anti-
microb. Chemother. 30:571–585. http://dx.doi.org/10.1093/jac/30.5.571.
29. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K,
Lindegardh N, Singhasivanon P, White NJ, Nosten F. 2011. Dihydro-
artemisinin-piperaquine versus chloroquine in the treatment of Plasmo-
dium vivax malaria in Thailand: a randomized controlled trial. Clin. In-
fect. Dis. 53:977–984. http://dx.doi.org/10.1093/cid/cir631.
30. Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A,
Edstein MD, Laihad F, Ebsworth EP, Anstey NM, Tjitra E, Price RN.
2007. Therapeutic response of multidrug-resistant Plasmodium falcipa-
rum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in
southern Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg. 101:351–359.
http://dx.doi.org/10.1016/j.trstmh.2006.06.008.
31. Ding XC, Ubben D, Wells TN. 2012. A framework for assessing the risk
of resistance for anti-malarials in development. Malar. J. 11:292. http://dx
.doi.org/10.1186/1475-2875-11-292.
32. Adjalley SH, Johnston GL, Li T, Eastman RT, Ekland EH, Eappen AG,
Richman A, Sim BK, Lee MC, Hoffman SL, Fidock DA. 2011. Quanti-
tative assessment of Plasmodium falciparum sexual development reveals
potent transmission-blocking activity by methylene blue. Proc. Natl.
Acad. Sci. U. S. A. 108:E1214–E1223. http://dx.doi.org/10.1073/pnas
.1112037108.
33. van Pelt-Koops JC, Pett HE, Graumans W, van der Vegte-Bolmer M,
van Gemert GJ, Rottmann M, Yeung BK, Diagana TT, Sauerwein RW.
2012. The spiroindolone drug candidate NITD609 potently inhibits ga-
metocytogenesis and blocks Plasmodium falciparum transmission to
anopheles mosquito vector. Antimicrob. Agents Chemother. 56:3544–
3548. http://dx.doi.org/10.1128/AAC.06377-11.
34. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. 2007. Drugs for bad
bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug
Discov. 6:29–40. http://dx.doi.org/10.1038/nrd2201.
35. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH,
Smithson DC, Connelly M, Clark J, Zhu F, Jimenez-Diaz MB, Martinez
MS, Wilson EB, Tripathi AK, Gut J, Sharlow ER, Bathurst I, El Mazouni
F, Fowble JW, Forquer I, McGinley PL, Castro S, Angulo-Barturen I,
Ferrer S, Rosenthal PJ, Derisi JL, Sullivan DJ, Lazo JS, Roos DS, Riscoe
MK, Phillips MA, Rathod PK, Van Voorhis WC, Avery VM, Guy RK.
2010. Chemical genetics of Plasmodium falciparum. Nature 465:311–315.
http://dx.doi.org/10.1038/nature09099.
36. Gamo FJ, Sanz LM, Vidal J, de Cozar C, Alvarez E, Lavandera JL,
Vanderwall DE, Green DV, Kumar V, Hasan S, Brown JR, Peishoff CE,
Cardon LR, Garcia-Bustos JF. 2010. Thousands of chemical starting
points for antimalarial lead identification. Nature 465:305–310. http://dx
.doi.org/10.1038/nature09107.
37. Gagaring K, Borboa R, Francek C, Chen Z, Buenviaje J, Plouffe D,
Winzeler E, Brinker A, Diagana T, Taylor J, Glynne R, Chatterjee A,
Kuhen K. 2010. Novartis-GNF Malaria Box. EMBL-EBI, Hinxton, Cam-
bridgeshire, United Kingdom. https://www.ebi.ac.uk/chemblntd.
38. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K,
Nagle A, Adrian F, Matzen JT, Anderson P, Nam TG, Gray NS,
Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou
Y,Winzeler EA. 2008. In silico activity profiling reveals the mechanism of
action of antimalarials discovered in a high-throughput screen. Proc.
Natl. Acad. Sci. U. S. A. 105:9059–9064. http://dx.doi.org/10.1073/pnas
.0802982105.
39. Gego A, Silvie O, Franetich JF, Farhati K, Hannoun L, Luty AJ,
Sauerwein RW, Boucheix C, Rubinstein E, Mazier D. 2006. New ap-
proach for high-throughput screening of drug activity on Plasmodium
liver stages. Antimicrob. Agents Chemother. 50:1586–1589. http://dx.doi
.org/10.1128/AAC.50.4.1586-1589.2006.
40. Buchholz K, Burke TA, Williamson KC, Wiegand RC, Wirth DF, Marti
M. 2011. A high-throughput screen targeting malaria transmission stages
opens new avenues for drug development. J. Infect. Dis. 203:1445–1453.
http://dx.doi.org/10.1093/infdis/jir037.
41. Chattopadhyay R, Velmurugan S, Chakiath C, Andrews Donkor L,
Milhous W, Barnwell JW, Collins WE, Hoffman SL. 2010. Establish-
ment of an in vitro assay for assessing the effects of drugs on the liver stages
of Plasmodium vivax malaria. PLoS One 5:e14275. http://dx.doi.org/10
.1371/journal.pone.0014275.
42. Dembele L, Gego A, Zeeman AM, Franetich JF, Silvie O, Rametti A, Le
Grand R, Dereuddre-Bosquet N, Sauerwein R, van Gemert GJ, Vaillant
JC, Thomas AW, Snounou G, Kocken CH, Mazier D. 2011. Towards an
in vitro model of Plasmodium hypnozoites suitable for drug discovery.
PLoS One 6:e18162. http://dx.doi.org/10.1371/journal.pone.0018162.
43. Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J,
Mather MW, Delves MJ, Shackleford DM, Saenz FE, Morrisey JM,
Steuten J, Mutka T, Li Y, Wirjanata G, Ryan E, Duffy S, Kelly JX,
Sebayang BF, Zeeman AM, Noviyanti R, Sinden RE, Kocken CH, Price
RN, Avery VM, Angulo-Barturen I, Jimenez-Diaz MB, Ferrer S, Her-
reros E, Sanz LM, Gamo FJ, Bathurst I, Burrows JN, Siegl P, Guy RK,
Winter RW, Vaidya AB, Charman SA, Kyle DE, Manetsch R, Riscoe
MK. 2013. Quinolone-3-diarylethers: a new class of antimalarial drug. Sci.
Transl. Med. 5:177ra137. http://dx.doi.org/10.1126/scitranslmed
.3005029.
44. Slavic K, Delves MJ, Prudencio M, Talman AM, Straschil U, Derbyshire
ET, Xu Z, Sinden RE, Mota MM, Morin C, Tewari R, Krishna S, Staines
HM. 2011. Use of a selective inhibitor to define the chemotherapeutic
potential of the plasmodial hexose transporter in different stages of the
parasite’s life cycle. Antimicrob. Agents Chemother. 55:2824–2830. http:
//dx.doi.org/10.1128/AAC.01739-10.
45. McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Nagle A, Simon
O, Yeung BK, Chatterjee AK, McCormack SL, Manary MJ, Zeeman
AM, Dechering KJ, Kumar TR, Henrich PP, Gagaring K, Ibanez M,
Kato N, Kuhen KL, Fischli C, Rottmann M, Plouffe DM, Bursulaya B,
Meister S, Rameh L, Trappe J, Haasen D, Timmerman M, Sauerwein
RW, Suwanarusk R, Russell B, Renia L, Nosten F, Tully DC, Kocken
CH, Glynne RJ, Bodenreider C, Fidock DA, Diagana TT, Winzeler EA.
2013. Targeting Plasmodium PI(4)K to eliminate malaria. Nature 504:
248–253. http://dx.doi.org/10.1038/nature12782.
46. McNamara C, Winzeler EA. 2011. Target identification and validation of
novel antimalarials. Future Microbiol. 6:693–704. http://dx.doi.org/10
.2217/fmb.11.45.
47. Tarun AS, Peng X, Dumpit RF, Ogata Y, Silva-Rivera H, Camargo N,
Daly TM, Bergman LW, Kappe SH. 2008. A combined transcriptome
and proteome survey of malaria parasite liver stages. Proc. Natl. Acad. Sci.
U. S. A. 105:305–310. http://dx.doi.org/10.1073/pnas.0710780104.
48. Khan SM, Franke-Fayard B, Mair GR, Lasonder E, Janse CJ, Mann M,
Waters AP. 2005. Proteome analysis of separated male and female game-
tocytes reveals novel sex-specific Plasmodium biology. Cell 121:675–687.
http://dx.doi.org/10.1016/j.cell.2005.03.027.
49. Silvestrini F, Lasonder E, Olivieri A, Camarda G, van Schaijk B, San-
chez M, Younis Younis S, Sauerwein R, Alano P. 2010. Protein export
marks the early phase of gametocytogenesis of the humanmalaria parasite
Plasmodium falciparum.Mol. Cell. Proteomics 9:1437–1448. http://dx.doi
.org/10.1074/mcp.M900479-MCP200.
50. Treeck M, Sanders JL, Elias JE, Boothroyd JC. 2011. The phosphopro-
teomes of Plasmodium falciparum and Toxoplasma gondii reveal unusual
adaptations within and beyond the parasites’ boundaries. Cell Host Mi-
crobe 10:410–419. http://dx.doi.org/10.1016/j.chom.2011.09.004.
KAF156 Inhibits Malaria Parasite at Multiple Stages
September 2014 Volume 58 Number 9 aac.asm.org 5067
